Cargando…

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

PURPOSE: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shan, Chen, Kai, Kong, Xuehua, Tian, Wenjun, Niu, Siqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058005/
https://www.ncbi.nlm.nih.gov/pubmed/35510161
http://dx.doi.org/10.2147/IDR.S357396
_version_ 1784698028230180864
author Sun, Shan
Chen, Kai
Kong, Xuehua
Tian, Wenjun
Niu, Siqiang
author_facet Sun, Shan
Chen, Kai
Kong, Xuehua
Tian, Wenjun
Niu, Siqiang
author_sort Sun, Shan
collection PubMed
description PURPOSE: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China. METHODS: CRE isolates and their clinical information were collected from 22 hospitals covering all the five regions across Chongqing between January 1, 2016 and December 31, 2017. PCR was used to screen for common carbapenemase genes. And minimum inhibitory concentrations (MICs) were determined by broth microdilution method. RESULTS: A total of 312 unduplicated CRE isolates (eg, 206 Klebsiella pneumoniae, 43 Escherichia coli, and 42 Enterobacter cloacae) were collected during the two-year study period. Among these CRE isolates, 92.3% carried carbapenemase genes, with a majority of isolates carrying single bla(KPC-2) (47.1%) or single bla(NDM/IPM) (36.2%) and 8.9% of isolates carrying two or three carbapenemase genes. Notably, 95.6% (197/206) K. pneumoniae, 86.0% (37/43) E. coli and 88.1% (37/42) E. cloacae harbored carbapenemase genes. In addition, bla(KPC-2) was prevalent in K. pneumoniae (70.4%), while bla(NDM) was predominant in E. coli (83.7%) and E. cloacae (78.6%). Besides, only metallo-β-lactamase (MBL) genes were detected in the CRE isolates from children. Overall, 0.0%, 48.1%, 59.0%, 61.5% and 63.1% of the CRE isolates were resistant to ATM/AVI, CAZ/AVI, nitrofurantoin, amikacin and trimethoprim/sulfamethoxazole, respectively. 99.7% of the total 312 isolates could be killed by ATM/AVI with the MIC 1 μg/mL, whereas CAZ/AVI showed good antibacterial activity (98.0% susceptible) against the bla(KPC-2)-carriers with the MIC(50/90) values of 1/4 μg/mL. CONCLUSION: The distribution features of carbapenemase genes in Chongqing were comprehensively illustrated in terms of species and sources of CRE for the first time in this multi-center study that covered all the geographical locations across Chongqing. ATM/AVI showed superior activity against all CRE isolates regardless of their genotype, whereas CAZ/AVI was active against almost all KPC-producers.
format Online
Article
Text
id pubmed-9058005
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90580052022-05-03 Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China Sun, Shan Chen, Kai Kong, Xuehua Tian, Wenjun Niu, Siqiang Infect Drug Resist Original Research PURPOSE: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China. METHODS: CRE isolates and their clinical information were collected from 22 hospitals covering all the five regions across Chongqing between January 1, 2016 and December 31, 2017. PCR was used to screen for common carbapenemase genes. And minimum inhibitory concentrations (MICs) were determined by broth microdilution method. RESULTS: A total of 312 unduplicated CRE isolates (eg, 206 Klebsiella pneumoniae, 43 Escherichia coli, and 42 Enterobacter cloacae) were collected during the two-year study period. Among these CRE isolates, 92.3% carried carbapenemase genes, with a majority of isolates carrying single bla(KPC-2) (47.1%) or single bla(NDM/IPM) (36.2%) and 8.9% of isolates carrying two or three carbapenemase genes. Notably, 95.6% (197/206) K. pneumoniae, 86.0% (37/43) E. coli and 88.1% (37/42) E. cloacae harbored carbapenemase genes. In addition, bla(KPC-2) was prevalent in K. pneumoniae (70.4%), while bla(NDM) was predominant in E. coli (83.7%) and E. cloacae (78.6%). Besides, only metallo-β-lactamase (MBL) genes were detected in the CRE isolates from children. Overall, 0.0%, 48.1%, 59.0%, 61.5% and 63.1% of the CRE isolates were resistant to ATM/AVI, CAZ/AVI, nitrofurantoin, amikacin and trimethoprim/sulfamethoxazole, respectively. 99.7% of the total 312 isolates could be killed by ATM/AVI with the MIC 1 μg/mL, whereas CAZ/AVI showed good antibacterial activity (98.0% susceptible) against the bla(KPC-2)-carriers with the MIC(50/90) values of 1/4 μg/mL. CONCLUSION: The distribution features of carbapenemase genes in Chongqing were comprehensively illustrated in terms of species and sources of CRE for the first time in this multi-center study that covered all the geographical locations across Chongqing. ATM/AVI showed superior activity against all CRE isolates regardless of their genotype, whereas CAZ/AVI was active against almost all KPC-producers. Dove 2022-04-27 /pmc/articles/PMC9058005/ /pubmed/35510161 http://dx.doi.org/10.2147/IDR.S357396 Text en © 2022 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Shan
Chen, Kai
Kong, Xuehua
Tian, Wenjun
Niu, Siqiang
Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
title Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
title_full Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
title_fullStr Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
title_full_unstemmed Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
title_short Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
title_sort genetic diversity and in vitro activity of aztreonam/avibactam and ceftazidime/avibactam against carbapenem-resistant enterobacterales: a multi-center study in southwest china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058005/
https://www.ncbi.nlm.nih.gov/pubmed/35510161
http://dx.doi.org/10.2147/IDR.S357396
work_keys_str_mv AT sunshan geneticdiversityandinvitroactivityofaztreonamavibactamandceftazidimeavibactamagainstcarbapenemresistantenterobacteralesamulticenterstudyinsouthwestchina
AT chenkai geneticdiversityandinvitroactivityofaztreonamavibactamandceftazidimeavibactamagainstcarbapenemresistantenterobacteralesamulticenterstudyinsouthwestchina
AT kongxuehua geneticdiversityandinvitroactivityofaztreonamavibactamandceftazidimeavibactamagainstcarbapenemresistantenterobacteralesamulticenterstudyinsouthwestchina
AT tianwenjun geneticdiversityandinvitroactivityofaztreonamavibactamandceftazidimeavibactamagainstcarbapenemresistantenterobacteralesamulticenterstudyinsouthwestchina
AT niusiqiang geneticdiversityandinvitroactivityofaztreonamavibactamandceftazidimeavibactamagainstcarbapenemresistantenterobacteralesamulticenterstudyinsouthwestchina